Stephan Kanzler
Overview
Explore the profile of Stephan Kanzler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheck M, Goetze T, Ettrich T, Schmalenberg H, Clemens M, Mahlberg R, et al.
Oncol Res Treat
. 2024 Sep;
47(11):549-560.
PMID: 39250905
Introduction: In squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line...
2.
Dorman K, Boeck S, Caca K, Reichert M, Ettrich T, Oettle H, et al.
Lancet Gastroenterol Hepatol
. 2024 Aug;
9(10):935-943.
PMID: 39159648
Background: A standardised dose-reduction strategy has not been established for the widely used gemcitabine plus nab-paclitaxel regimen in patients with metastatic pancreatic ductal adenocarcinoma. We aimed to investigate the efficacy...
3.
Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, et al.
Lancet Gastroenterol Hepatol
. 2024 Jun;
9(8):734-744.
PMID: 38870977
Background: There is an unmet need for effective therapies in pretreated advanced biliary tract cancer. We aimed to evaluate the efficacy of nanoliposomal irinotecan and fluorouracil plus leucovorin compared with...
4.
Heinrich K, Heinemann V, Stintzing S, Muller L, Ettrich T, Buchner-Steudel P, et al.
Oncol Res Treat
. 2024 Apr;
47(6):251-261.
PMID: 38565089
Introduction: S-1 has been shown to be an effective adjuvant treatment option for East Asian patients who underwent gastrectomy for stage II/III gastric cancer. We conducted a phase I/II study...
5.
Schmoll H, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, et al.
Br J Cancer
. 2023 Nov;
130(2):233-241.
PMID: 37996507
Background: FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification...
6.
Dorman K, Boeck S, Snijder R, Siveke J, Schenk M, Mayerle J, et al.
Curr Oncol
. 2023 Jun;
30(6):5828-5834.
PMID: 37366919
This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the "Burden of Therapy" (BOTh) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients...
7.
Dreher M, Grohe C, Hartmann N, Kanzler S, Kraft K, Sarrazin C, et al.
Adv Ther
. 2022 Apr;
39(6):3011-3018.
PMID: 35419650
Introduction: Enhancement of mucociliary clearance (MCC) might be a potential target in treating COVID-19. The phytomedicine ELOM-080 is an MCC enhancer that is used to treat inflammatory respiratory diseases. Patients/methods:...
8.
Sivanathan V, Utz C, Thomaidis T, Forster F, Stahl M, Lordick F, et al.
Ultraschall Med
. 2022 Feb;
43(5):514-521.
PMID: 35226933
Purpose: The role of EUS before or after neoadjuvant chemotherapy (nCTX) in advanced esophagogastric cancer (EGC) is still unclear. The phase II NEOPECX trial evaluated perioperative chemotherapy with or without...
9.
Modest D, Martens U, Riera-Knorrenschild J, Greeve J, Florschutz A, Wessendorf S, et al.
J Clin Oncol
. 2019 Oct;
37(35):3401-3411.
PMID: 31609637
Purpose: This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with...
10.
Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience P, Ruessel J, Hegewisch-Becker S, et al.
BMC Cancer
. 2016 Sep;
16:699.
PMID: 27582078
Background: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with...